Biotech

Kyprolis data fuel Amgen oncology aspirations

Kyprolis data fuel Amgen oncology aspirations

By

Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.

Biotech Report: Ultra Man

Biotech Report: Ultra Man

By

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

Lemtrada US rejection snarls Sanofi

Lemtrada US rejection snarls Sanofi

By

The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.

Iclusig is back in US

Iclusig is back in US

Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

By

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Report: Dendreon looking for buyer

The prostate cancer drug company is reportedly seeking a buyer to turn things around.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

OPDP sends Warning Letter to Acorda

By

The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.

Cubist buying spree bolsters antibiotic roster

By

The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.

In wake of HCV setback, Vertex to contain marketing spend

By

While a strong launch of CF drug Kalydeco helped to hike the biotech's forecast, hep. C contender VTX-135 was hit with a partial clinical hold.

Unabated Tecfidera growth propels Biogen

By

Biogen Idec raised its full-year guidance on Tecfidera launch sales, as the MS market continues its growth trajectory.

Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline

A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.

Business briefs: Mayo Clinic, GSK, Lundbeck, Biogen Idec

Mayo Clinic says 70% of adults are on an Rx, with 25% of older women on an anti-depressant; GSK sinks $24M into rare-disease venture fund; Lundbeck restructures, and may kill 50 jobs; and Tecfidera is reportedly on-track for blockbuster sales estimates but still faces reimbursement hurdles.

R&D chief's spring-cleaning sweeps through Merck labs

By

Roger Perlmutter has begun to trim the fat off Merck's lackluster pipeline.

Navidea deploying MSLs in launch of new diagnostic agent

Navidea deploying MSLs in launch of new diagnostic agent

By

Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.

Business Briefs: Manhattan Research, KPMG, Scioderm and GSK

Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment.

Pharmas to biotechs: let's make a deal

Pharmas to biotechs: let's make a deal

By

Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.

Data show Gilead's sofosbuvir has 'clean' safety profile

By

Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.

Q&A: BIO's Jim Greenwood

Q&A: BIO's Jim Greenwood

By

BIO chief Jim Greenwood talks policy priorities and previews the group's International Convention, now underway in Chicago.

FDA says competing biologic ads both misled

By

One is a sales aid, and one is a consumer brochure, but both ads -- for CSL Behring's Zemaira and for Talecris' Prolastin -- are false or misleading, FDA said in a pair of untitled letters.

Biosimilars mean competition, not marketing oblivion, for biologic brands

By

Far from sapping promotional budgets, biosimilars could spur marketing by makers of follow-on and original biologic alike, experts say.

Generic Lovenox takes step closer to reality, analyst says

By

Sandoz, the generics division of Novartis, is soliciting pre-orders for Sanofi-Aventis blood thinner Lovenox—actions that seem to suggest generic approval of the megablockbuster may be coming soon, one analyst says.

Senate health bill pharma-friendly on biologics, price controls

By

The Senate health reform bill would maintain the ban on price controls in the Medicare prescription drug benefit and establish a 12-year data exclusivity period for biologics.

EMD Serono launches male fertility education campaign

EMD Serono launches male fertility education campaign

By

EMD Serono is partnering with Men's Health Network on a patient education campaign aimed at raising awareness of male infertility.

Lilly looks homeward for communications chief

By

Lilly named former Indianapolis mayor Bart Peterson to lead its communications and corporate affairs functions.

Last chance to grab glory

Last chance to grab glory

If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.

Biotech launches personalized cancer treatment website

By

Champions Biotechnology, a company offering personalized cancer data for patients and physicians, launched a new website: PersonalizedCancerTreatment.com.

Non-compliance, requests for generics on the rise, says survey

By

Physicians say patient compliance is getting worse, and they're hearing more requests for generic or OTC alternatives to prescribed medications as the economic malaise takes its toll, according to a PriMed survey.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters